Advances in RSV vaccine research and development - A global agenda

Vaccine

Volumn 34, Issue 26, 2016, Pages 2870-2875

  Higgins, Deborah ^a   Trujillo, Carrie ^a   Keech, Cheryl ^a  

^a PATH   (United States)

Author keywords

Research and development; Respiratory syncytial virus; Vaccine

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CONGENITAL HEART DISEASE; DEVELOPMENTAL STAGE; FEASIBILITY STUDY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; LOWEST INCOME GROUP; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; CLINICAL TRIAL (TOPIC); HUMAN RESPIRATORY SYNCYTIAL VIRUS; MEDICAL RESEARCH; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 84963988148     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.109     Document Type: Article

References (32)

1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
3. Hall C.B. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 2012, 12:92-97.
4. Dudas R.A., Karron R.A. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998, 11:430-439.
5. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
6. Trends in maternal mortality: 1990-2010 WHO, UNICEF, UNFPA, and The World Bank estimates 2012, WHO, Geneva, [accessed 05.11.15]. http://apps.who.int/iris/bitstream/10665/44874/1/9789241503631_eng.pdf.
7. Anderson L.J., Dormitzer P.R., Nokes D.J., Rappuoli R., Roca A., Graham B.S. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31(Suppl. 2):B209-B215.
8. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia - RSV recombinants or RSV. Vaccine 1992, 10:475-484.
9. Groothuis J.R., Hoopes J.M., Hemming V.G. Prevention of serious respiratory syncytial virus-related illness. II: immunoprophylaxis. Adv Ther 2011, 28:110-125.
10. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
11. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89:449-463.
12. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89:435-448.
13. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
14. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
15. Kim H.W., Leikin S.L., Arrobio J., Brandt C.D., Chanock R.M., Parrott R.H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976, 10:75-78.
16. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24:197-202.
17. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859-865.
18. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
19. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82:2881-2888.
20. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986, 57:721-728.
21. Hall C.B., Weinberg G.A., Iwane M.K., Blumkin A.K., Edwards K.M., Staat M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
22. Karron R.A., Luongo C., Thumar B., Loehr K.M., Englund J.A., Collins P.L., et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med 2015, 7:312ra175.
23. Bacharier L.B., Cohen R., Schweiger T., Yin-Declue H., Christie C., Zheng J., et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012, 130:91-100.e3.
24. Bosch A.A., Biesbroek G., Trzcinski K., Sanders E.A., Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLOS Pathog 2013, 9:e1003057.
25. Modjarrad K., Giersing B., Kaslow D.C., Smith P.G., Moorthy V.S. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine 2016, 34:190-197. WHO RSV Vaccine Consultation Expert Group.
26. Glenn G.M., Smith G., Fries L., Raghunandan R., Lu H., Zhou B., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle, vaccine. Vaccine 2013, 31(January):524-532.
27. Groothuis J.R., Simoes E.A., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993, 329:1524-1530.
28. Prince G.A., Horswood R.L., Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985, 55:517-520.
29. Walsh E.E., Schlesinger J.J., Brandriss M.W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984, 43:756-758.
30. Liljeroos L., Krzyzaniak M.A., Helenius A., Butcher S.J. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 2013, 110:11133-11138.
31. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
32. Ngwuta J.O., Chen M., Modjarrad K., Joyce M.G., Kanekiyo M., Kumar A., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015, 7:309ra162.